Canada bans Indian API maker; Congress looks at antibiotics development; Former Pfizer site proves tricky for town;

@FiercePharma: Eylea gets yet another approval, this one in Japan. More | Follow @FiercePharma

@EricPFierce: Potentially bad news for Amphastar and its $155.7M deal if Sanofi makes insulin for Mannkind. Article | Follow @EricPFierce

@CarlyHFierce: Inversion pushback won't scare Horizon Pharma out of Ireland move. Story | Follow @CarlyHFierce

> Canada has ordered Indian API maker IPCA to stop exporting there after the FDA reviewed information that led the agency to ban its products. Story

> The U.S. Congress is considering more legislation that could lead to the development of more drugs to overcome antibiotic resistance. Story

> Lake Forest, IL-based Akorn ($AKRX) last year had about $320 million in sales but expects to use acquisitions to become a $1 billion revenue generator. Report

Medical Device News

@FierceMedDev: Zimmer partners with MiMedx to sell bioimplants to promote healing. Article | Follow @FierceMedDev

@MichaelGFierce: Vaxxas' nanopatch garners WHO support in search of #polio vax application. Story | Follow @MichaelGFierce

@VarunSaxena2: Court ruling against FDA should enable more combination products to be classified as devices. Article | Follow @VarunSaxena2

@EmilyWFierce: British startup launches crowdfunding effort for 3-D printed orthotic devices. More | Follow @EmilyWFierce

> University of Louisville working on 'bioficial heart' using 3-D printing. Story

> Physicians defend power morcellator devices amid industry fallout. Article

Biotech News

@FierceBiotech: FierceBiotech's 2014 Fierce 15. Congrats to those who made the list! | Follow @FierceBiotech

@JohnCFierce: Always fun to watch the web traffic explode when we blast the Fierce 15. | Follow @JohnCFierce

@DamianFierce: Merck KGaA gets around to that big deal it's been talking up: $SIAL for $17B. More | Follow @DamianFierce

> Tekmira hammers out a way to get its Ebola drug to patients. News

> Amgen pushes for early FDA OK of leukemia drug blinatumomab. Story

> Regeneron touts its allergy drug as a blockbuster in waiting. Article

CRO News

> Packaging outfit PCI buys trial supplier Biotec. News

> Survey says: Big CROs are only getting bigger. Report

> CRO FlowMetric gets into diagnostics with new spinout. Story

> TransCelerate dishes on risk-based monitoring. Item

> Covance borrows Fresenius' data to improve kidney treatments. Article

Biotech IT News

> Vivametrica makes pitch for mHealth data aggregation and analysis market. Report

> Stanford and Duke to trial Apple's HealthKit for remote data collection. More

> Merck survey finds patients willing to share NGS data with pharma companies. Story

> BBK bags $3M to expand its eClinical suite. Item

> AstraZeneca opens Indian IT center as 13-year outsourcing experiment nears end. Article

Animal Health News

> Work on the National Bio and Agro-Defense Facility continues. More

> EU gives nod to Merck's poultry vaccine to fight infectious bronchitis. Report

> Phibro reports strong sales in animal growth and nutrition sectors. Article

> Will Zoetis stand alone when Big Pharma's music stops? More

> Packaging outfit PCI buys trial supplier Biotec. Story

And Finally... A former Pfizer ($PFE) site in Morris Plains, NJ, is in legal limbo. Story

Suggested Articles

AstraZeneca and Brazil have expanded their deal for a possible COVID-19 vaccine, this time to the tune of $360 million.

Novavax expects to churn out enough vaccines in 2021 to meet U.S. demand; experts slam the medical and political risks of Russia's unproven vaccine.

Novavax will have billions of doses of COVID-19 vaccine capacity next year and could single-handedly meet U.S. demand, executives said.